|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weiderpass E, Antoine J, Bray FI, Oh JK
and Arbyn M: Trends in corpus uteri cancer mortality in member
states of the European Union. Eur J Cancer. 50:1675–1684. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duong LM, Wilson RJ, Ajani UA, Singh SD
and Eheman CR: Trends in endometrial cancer incidence rates in the
United States, 1999–2006. J Womens Health (Larchmt). 20:1157–1163.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edwards BK, Noone AM, Mariotto AB, Simard
EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA,
et al: Annual Report to the Nation on the status of cancer,
1975–2010, featuring prevalence of comorbidity and impact on
survival among persons with lung, colorectal, breast, or prostate
cancer. Cancer. 120:1290–1314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li X, Zheng S, Chen S, Qin F, Lau S and
Chen Q: Trends in gynaecological cancers in the largest obstetrics
and gynaecology hospital in China from 2003 to 2013. Tumour Biol.
36:4961–4966. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bansal N, Yendluri V and Wenham RM: The
molecular biology of endometrial cancers and the implications for
pathogenesis, classification and targeted therapies. Cancer
Control. 16:8–13. 2009.PubMed/NCBI
|
|
7
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Setiawan VW, Yang HP, Pike MC, McCann SE,
Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, et al:
Type I and II endometrial cancers: Have they different risk
factors? J Clin Oncol. 31:2607–2618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zemel S, Bartolomei MS and Tilghman SM:
Physical linkage of two mammalian imprinted genes, H19 and
insulin-like growth factor 2. Nat Genet. 2:61–65. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y and Tycko B: Monoallelic
expression of the human H19 gene. Nat Genet. 1:40–44. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pachnis V, Brannan CI and Tilghman SM: The
structure and expression of a novel gene activated in early mouse
embryogenesis. EMBO J. 7:673–681. 1988.PubMed/NCBI
|
|
12
|
Hao Y, Crenshaw T, Moulton T, Newcomb E
and Tycko B: Tumour-suppressor activity of H19 RNA. Nature.
365:764–767. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng
R, Wang Y, Huang J, Xu M, Yan J and Yu J: lncRNA H19/miR-675 axis
represses prostate cancer metastasis by targeting TGFBI. FEBS J.
281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berteaux N, Lottin S, Monté D, Pinte S,
Quatannens B, Coll J, Hondermarck H, Curgy JJ, Dugimont T and
Adriaenssens E: H19 mRNA-like noncoding RNA promotes breast cancer
cell proliferation through positive control by E2F1. J Biol Chem.
280:29625–29636. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Medrzycki M, Zhang Y, Zhang W, Cao K, Pan
C, Lailler N, McDonald JF, Bouhassira EE and Fan Y: Histone h1.3
suppresses h19 noncoding RNA expression and cell growth of ovarian
cancer cells. Cancer Res. 74:6463–6473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matouk IJ, Raveh E, Abu-lail R, Mezan S,
Gilon M, Gershtain E, Birman T, Gallula J, Schneider T, Barkali M,
et al: Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys
Acta. 1843:1414–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan
Z and Ai K: H19 promotes pancreatic cancer metastasis by
derepressing let-7's suppression on its target HMGA2-mediated EMT.
Tumour Biol. 35:9163–9169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanos V, Ariel I, Prus D, De-Groot N and
Hochberg A: H19 and IGF2 gene expression in human normal,
hyperplastic and malignant endometrium. Int J Gynecol Cancer.
14:521–525. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lottin S, Adriaenssens E, Berteaux N,
Lepretrê A, Vilain MO, Denhez E, Coll J, Dugimont T and Curgy JJ:
The human H19 gene is frequently overexpressed in myometrium and
stroma during pathological endometrial proliferative events. Eur J
Cancer. 41:168–177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mokhtar NM, Ramzi NH, Yin-Ling W, Rose IM,
Mohd Dali AZ Hatta and Jamal R: Laser capture microdissection with
genome-wide expression profiling displayed gene expression
signatures in endometrioid endometrial cancer. Cancer Invest.
30:156–164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matouk IJ, DeGroot N, Mezan S, Ayesh S,
Abu-lail R, Hochberg A and Galun E: The H19 non-coding RNA is
essential for human tumor growth. PloS one. 2:e8452007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Sun Y, Yi J, Wang X, Liang J, Pan
Z, Li L and Jiang G: Targeting H19 by lentivirus-mediated RNA
interference increases A549 cell migration and invasion. Exp Lung
Res. 1–8. 2016.(Epub ahead of print).
|
|
26
|
Zhang E, Li W, Yin D, De W, Zhu L, Sun S
and Han L: c-Myc-regulated long non-coding RNA H19 indicates a poor
prognosis and affects cell proliferation in non-small-cell lung
cancer. Tumour Biol. 37:4007–4015. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshimizu T, Miroglio A, Ripoche MA,
Gabory A, Vernucci M, Riccio A, Colnot S, Godard C, Terris B,
Jammes H and Dandolo L: The H19 locus acts in vivo as a tumor
suppressor. Proc Natl Acad Sci USA. 105:12417–12422. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang L, Cai Y, Zhao X, Jia X, Zhang J, Liu
J, Zhen H, Wang T, Tang X, Liu Y and Wang J: Down-regulated long
non-coding RNA H19 inhibits carcinogenesis of renal cell carcinoma.
Neoplasma. 62:412–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi
Y and Guo J: Long noncoding RNA associated-competing endogenous
RNAs in gastric cancer. Sci Rep. 4:60882014.PubMed/NCBI
|
|
30
|
Hernandez JM, Elahi A, Clark CW, Wang J,
Humphries LA, Centeno B, Bloom G, Fuchs BC, Yeatman T and Shibata
D: miR-675 mediates downregulation of Twist1 and Rb in
AFP-secreting hepatocellular carcinoma. Ann Surg Oncol. 20:Suppl 3.
S625–S635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan
L and Chen JL: High expression of long non-coding RNA H19 is
required for efficient tumorigenesis induced by Bcr-Abl oncogene.
FEBS Lett. 588:1780–1786. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Min HY, Lee SC, Woo JK, Jung HJ, Park KH,
Jeong HM, Hyun SY, Cho J, Lee W, Park JE, et al: Essential role of
DNA methyltransferase 1-mediated transcription of insulin-like
growth factor 2 in resistance to histone deacetylase inhibitors.
Clin Cancer Res. pii: clincanres.0534.2016, 2016. (Epub ahead of
print).
|
|
33
|
Dugimont T, Montpellier C, Adriaenssens E,
Lottin S, Dumont L, Iotsova V, Lagrou C, Stéhelin D, Coll J and
Curgy JJ: The H19 TATA-less promoter is efficiently repressed by
wild-type tumor suppressor gene product p53. Oncogene.
16:2395–2401. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Long non-coding RNA H19 increases bladder cancer metastasis by
associating with EZH2 and inhibiting E-cadherin expression. Cancer
Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang L, Yang F, Yuan JH, Yuan SX, Zhou
WP, Huo XS, Xu D, Bi HS, Wang F and Sun SH: Epigenetic activation
of the MiR-200 family contributes to H19-mediated metastasis
suppression in hepatocellular carcinoma. Carcinogenesis.
34:577–586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang EB, Han L, Yin DD, Kong R, De W and
Chen J: c-Myc-induced, long, noncoding H19 affects cell
proliferation and predicts a poor prognosis in patients with
gastric cancer. Med Oncol. 31:9142014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J
and Fang G: Up-regulated long non-coding RNA H19 contributes to
proliferation of gastric cancer cells. FEBS J. 279:3159–3165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ayesh S, Matouk I, Schneider T, Ohana P,
Laster M, Al-Sharef W, De-Groot N and Hochberg A: Possible
physiological role of H19 RNA. Mol Carcinog. 35:63–74. 2002.
View Article : Google Scholar : PubMed/NCBI
|
